Azithromycin Resistance in Shiga Toxin-Producing Escherichia coli in France between 2004 and 2020 and Detection of mef(C)-mph(G) Genes
ABSTRACT
We described and characterized Shiga-toxin-producing Escherichia coli (STEC) strains with high levels of resistance to azithromycin isolated in France between 2004 and 2020. Nine of 1,715 (0.52%) STEC strains were resistant to azithromycin, with an increase since 2017. One isolate carried a plasmid-borne mef(C)-mph(G) gene combination, described here for the first time for E. coli. Azithromycin resistance, although rare, needs consideration, as this treatment may be useful in cases of STEC infection.
Get full access to this article.
View all available purchase options and get full access to this article.
REFERENCES
1.
Williams DM, Sreedhar SS, Mickell JJ, Chan JCM. 2002. Acute kidney failure: a pediatric experience over 20 years. Arch Pediatr Adolesc Med 156:893–900.
2.
Joseph A, Cointe A, Mariani Kurkdjian P, Rafat C, Hertig A. 2020. Shiga toxin-associated hemolytic uremic syndrome: a narrative review. Toxins 12:67.
3.
Cointe A, Birgy A, Bridier-Nahmias A, Mariani-Kurkdjian P, Walewski V, Lévy C, Cohen R, Fach P, Delannoy S, Bidet P, Bonacorsi S. 2020. Escherichia coli O80 hybrid pathotype strains producing Shiga toxin and ESBL: molecular characterization and potential therapeutic options. J Antimicrob Chemother 75:537–542.
4.
Ohara T, Kojio S, Taneike I, Nakagawa S, Gondaira F, Tamura Y, Gejyo F, Zhang H-M, Yamamoto T. 2002. Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response. Antimicrob Agents Chemother 46:3478–3483.
5.
Nitschke M, Sayk F, Härtel C, Roseland RT, Hauswaldt S, Steinhoff J, Fellermann K, Derad I, Wellhöner P, Büning J, Tiemer B, Katalinic A, Rupp J, Lehnert H, Solbach W, Knobloch JK-M. 2012. Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 307:1046–1052.
6.
Hicks LA, Taylor TH, Hunkler RJ. 2013. U.S. outpatient antibiotic prescribing, 2010. N Engl J Med 368:1461–1462.
7.
Fleming-Dutra KE, Demirjian A, Bartoces M, Roberts RM, Taylor TH, Hicks LA. 2018. Variations in antibiotic and azithromycin prescribing for children by geography and specialty—United States, 2013. Pediatr Infect Dis J 37:52–58.
8.
Seidman JC, Coles CL, Silbergeld EK, Levens J, Mkocha H, Johnson LB, Muñoz B, West SK. 2014. Increased carriage of macrolide-resistant fecal E. coli following mass distribution of azithromycin for trachoma control. Int J Epidemiol 43:1105–1113.
9.
Gomes C, Martínez-Puchol S, Palma N, Horna G, Ruiz-Roldán L, Pons MJ, Ruiz J. 2017. Macrolide resistance mechanisms in Enterobacteriaceae: focus on azithromycin. Crit Rev Microbiol 43:1–30.
10.
Pawlowski AC, Stogios PJ, Koteva K, Skarina T, Evdokimova E, Savchenko A, Wright GD. 2018. The evolution of substrate discrimination in macrolide antibiotic resistance enzymes. Nat Commun 9:112.
11.
Gomes C, Ruiz-Roldán L, Mateu J, Ochoa TJ, Ruiz J. 2019. Azithromycin resistance levels and mechanisms in Escherichia coli. Sci Rep 9:6089.
12.
Jost C, Bidet P, Carrère T, Mariani-Kurkdjian P, Bonacorsi S. 2016. Susceptibility of enterohaemorrhagic Escherichia coli to azithromycin in France and analysis of resistance mechanisms. J Antimicrob Chemother 71:1183–1187.
13.
Day M, Doumith M, Jenkins C, Dallman TJ, Hopkins KL, Elson R, Godbole G, Woodford N. 2017. Antimicrobial resistance in Shiga toxin-producing Escherichia coli serogroups O157 and O26 isolated from human cases of diarrhoeal disease in England, 2015. J Antimicrob Chemother 72:145–152.
14.
Leclercq R, Cantón R, Brown DFJ, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy C-J, Steinbakk M, Winstanley TG, Kahlmeter G. 2013. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19:141–160.
15.
Jones G, Pardos de la Gandara M, Herrera-Leon L, Herrera-Leon S, Varela Martinez C, Hureaux-Roy R, Abdallah Y, Nisavanh A, Fabre L, Renaudat C, Mossong J, Mattheus W, Huard C, Le Borgne C, de Valk H, Weill F-X, Jourdan-Da Silva N. 2019. Outbreak of Salmonella enterica serotype Poona in infants linked to persistent Salmonella contamination in an infant formula manufacturing facility, France, August 2018 to February. Euro Surveill 24:2019.
16.
Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput Biol 13:e1005595.
17.
Carattoli A, Hasman H. 2020. PlasmidFinder and in silico pMLST: identification and typing of plasmid replicons in whole-genome sequencing (WGS). Methods Mol Biol 2075:285–294.
18.
Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O. 2008. The RAST Server: rapid annotations using subsystems technology. BMC Genomics 9:75.
19.
Nonaka L, Maruyama F, Miyamoto M, Miyakoshi M, Kurokawa K, Masuda M. 2012. Novel conjugative transferable multiple drug resistance plasmid pAQU1 from Photobacterium damselae subsp. damselae isolated from marine aquaculture environment. Microbes Environ 27:263–272.
20.
Sugimoto Y, Suzuki S, Nonaka L, Boonla C, Sukpanyatham N, Chou H-Y, Wu J-H. 2017. The novel mef(C)–mph(G) macrolide resistance genes are conveyed in the environment on various vectors. J Glob Antimicrob Resist 10:47–53.
21.
Safdar N, Said A, Gangnon RE, Maki DG. 2002. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 288:996–1001.
22.
Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F, Mellmann A, Peters G, Karch H. 2012. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob Agents Chemother 56:3277–3282.
23.
Nassar FJ, Rahal EA, Sabra A, Matar GM. 2013. Effects of subinhibitory concentrations of antimicrobial agents on Escherichia coli O157:H7 Shiga toxin release and role of the SOS response. Foodborne Pathog Dis 10:805–812.
24.
Kakoullis L, Papachristodoulou E, Chra P, Panos G. 2019. Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview. J Infect 79:75–94.
25.
Ochoa TJ, Chen J, Walker CM, Gonzales E, Cleary TG. 2007. Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli. Antimicrob Agents Chemother 51:2837–2841.
26.
Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont H. 2000. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 44:2205–2206.
Information & Contributors
Information
Published In
Antimicrobial Agents and Chemotherapy
Volume 66 • Number 2 • 15 February 2022
eLocator: e01949-21
PubMed: 34871091
Copyright
© 2022 American Society for Microbiology. All Rights Reserved.
History
Received: 3 October 2021
Returned for modification: 27 October 2021
Accepted: 26 November 2021
Accepted manuscript posted online: 6 December 2021
Published online: 15 February 2022
KEYWORDS
Contributors
Metrics & Citations
Metrics
Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
View Options
Get Access
LOGIN OPTIONS
Check if you access through your login credentials or your institution to get full access on this article.
Non-Member Login Institutional LoginPURCHASE OPTIONS
Subscribe and get full access to this article